Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2020’, provides an overview of the Amyotrophic Lateral Sclerosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis

– The report reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Amyotrophic Lateral Sclerosis therapeutics and enlists all their major and minor projects

– The report assesses Amyotrophic Lateral Sclerosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

1st Bio Therapeutics Inc

AB Science SA

Above and Beyond Concierge Therapeutics LLC

AC Immune SA

Aclipse One Inc

Aclipse Therapeutics LLC

AcuraStem Inc

Table of Contents

Table of Contents

Introduction

Amyotrophic Lateral Sclerosis - Overview

Amyotrophic Lateral Sclerosis - Therapeutics Development

Amyotrophic Lateral Sclerosis - Therapeutics Assessment

Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development

Amyotrophic Lateral Sclerosis - Drug Profiles

Amyotrophic Lateral Sclerosis - Dormant Projects

Amyotrophic Lateral Sclerosis - Discontinued Products

Amyotrophic Lateral Sclerosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by 1st Bio Therapeutics Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by AB Science SA, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Above and Beyond Concierge Therapeutics LLC, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by AC Immune SA, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Aclipse One Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Aclipse Therapeutics LLC, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by AcuraStem Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Adare Pharma Solutions, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Affichem SA, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by AgoneX Biopharmaceuticals Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by AI Therapeutics Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by AL-S Pharma AG, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Alexion Pharmaceuticals Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by AlphaCognition Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Alsonex Pty Ltd, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Amicogen Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Amylyx Pharmaceutical Corp, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Anavex Life Sciences Corp, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Anima Biotech Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Ankar Pharma SL, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Annexon Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Apellis Pharmaceuticals Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Apic Bio Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Apogenix AG, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Applied Genetic Technologies Corp, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Aquilus Pharmaceuticals Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Relmada Therapeutics Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by reMYND NV, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by ReoStem LLC, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Retrotope Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Revalesio Corp, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Samus Therapeutics Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Sangamo Therapeutics Inc, H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Seelos Therapeutics, Inc., H2 2020

Amyotrophic Lateral Sclerosis – Pipeline by Seneca Biopharma Inc, H2 2020

Amyotrophic Lateral Sclerosis – Dormant Projects, H2 2020

Amyotrophic Lateral Sclerosis – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports